A recent study showed that the inhibition of CNS c-Abl upon nilotinib treatment reduced Aβ load and tau phosphorylation in AD experimental models and suggested nilotinib as a suitable preclinical candidate for AD therapies [38]. This evidence concerns the gene MAPT and Alzheimer disease.